The content on this site is intended for healthcare professionals only
Dr Gyawali meets with ecancertv at ESMO 2016 to discuss the value of negative trials, considering the slow progression in treating ovarian cancer.
He considers statistically positive studies that have limited benefit for patient survivals, trials finding improved progression-free survival but which fail for not meeting other primary endpoints, and the central importance of patient benefit in trial design.
Read Dr Gyawali’s article "Negative trials in ovarian cancer: is there such a thing as too much optimism?" here.
Dr Gyawali spoke further with ecancer about the balancing of risk and overall survival for patients treated with sorafenib, and contributes a regular blog with his views on recent research.
Prostate cancer
Enhancing head and neck oncology: Key insights from the conference
ESMO 2024: Optimising the personalisation of prostate cancer treatment
First-line chemotherapy with atezolizumab and bevacizumab significantly improves survival for R/M cervical cancer
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
The iCCaRE Consortium for Black Men - Addressing the disproportionate burden of prostate cancer
Lung cancer screening and treatment in the Philippines
Choosing Wisely in radiology
